Fifth Third Bancorp Purchases 315,858 Shares of Elanco Animal Health Incorporated $ELAN

Fifth Third Bancorp boosted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 10,291.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 318,927 shares of the company’s stock after buying an additional 315,858 shares during the period. Fifth Third Bancorp’s holdings in Elanco Animal Health were worth $7,632,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Elanco Animal Health during the first quarter worth about $2,065,000. Goldman Sachs Group Inc. lifted its holdings in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Empowered Funds LLC boosted its stake in Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after purchasing an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after purchasing an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Elanco Animal Health by 2,006.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after buying an additional 295,651 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $25.55 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. Elanco Animal Health Incorporated has a 1-year low of $13.39 and a 1-year high of $27.72. The firm has a market capitalization of $12.76 billion, a P/E ratio of -51.10, a price-to-earnings-growth ratio of 1.67 and a beta of 1.68. The company’s 50-day moving average is $23.55 and its 200 day moving average is $23.85.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business’s revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Insider Transactions at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Rajeev A. Modi bought 4,911 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research analyst reports. TD Cowen raised their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. JPMorgan Chase & Co. increased their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Citigroup boosted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.55.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.